Liangxue Ointment（Traditional Chinese Ointment）
Hand-Foot Syndrome
Explore 6 assets in Hand-Foot Syndrome →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Peking University Cancer Hospital & Institute
Modality
UNKNOWN
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06583369CT.gov The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI Drugs | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hand-Foot Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Liangxue Ointment（Traditional Chinese Ointment） (this asset) | Peking University Cancer Hospital & Institute | N/A | D · 30 |
| Adriamycin | Swiss Cancer Institute | P3 | BB |
| Mecobalamin | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P3 | B |
| Celecoxib | Affiliated Hospital of Qinghai University | P3 | B |
| Tazarotene | Dana-Farber Cancer Institute | P2 | CCC |
| Indometacinum | National Taiwan University Hospital | P2 | CCC |
| Nicotine | University of California, San Francisco | P2 | CCC |
| 0.1% uracil cream | Nanometics (d.b.a. PHD Biosciences) | P1/2 | CCC |
| Niacin | First People's Hospital of Hangzhou | P2 | CCC |
+3 more in the Hand-Foot Syndrome cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Liangxue Ointment（Traditional Chinese Ointment） in Hand-Foot Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/liangxue-ointmenttraditional-chinese-ointment-hand-foot-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →